Keywords: UK, Value-based pricing, Patient drug access, Stockholm Network, Myeloma UK

UK’s value-based pricing unlikely to improve patient drug access, says think tank

Article | 18 March 2011

The proposed reforms to the way that medicines are priced within the UK’s National Health Service are unlikely ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in